{"entity":{"id":"himalayas-1","kind":"trial","name":"A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)","aka":["Himalayas-1"],"tldr":"A phase 3 trial testing Rinzimetostat in prostate cancer, now recruiting.","summary":"A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1) is a phase 3 interventional study registered as NCT07723248, led by ORIC Pharmaceuticals with Bayer, and recruiting on the registry. Official title: A Phase 3, Randomised, Open-Label Study of Rinzimetostat (ORIC-944) in Combination With Darolutamide Compared With ARPI or Docetaxel in Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone Acetate (Himalayas-1). Planned enrolment is 600 participants (estimated). The study started in 2026-08-03 and primary completion is expected in 2028-03. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07723248","url":"https://clinicaltrials.gov/study/NCT07723248"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mcrpc"],"sections":[],"technologies":[],"targets":[],"drugs":["rinzimetostat"],"companies":["oric-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07723248","phase":"3","setting":"A Phase 3, Randomized, Open-Label Study of Rinzimetostat (ORIC-944) in Combination With Darolutamide Compared With ARPI or Docetaxel in Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone Acetate (Himalayas-1)","sponsor":"ORIC Pharmaceuticals","participation":[{"nct":"NCT07723248","source":"https://clinicaltrials.gov/study/NCT07723248","fetchedAt":"2026-10-07T16:56:10.647Z","studySha256":"0338bf99523bedd5596510364def502e2ba25b86c9f7901e71d398574ac4daa9","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-05","leadSponsor":"ORIC Pharmaceuticals","collaboratorCount":1,"minimumAge":"18 Years","sex":"MALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":600,"enrolmentType":"ESTIMATED","siteCount":12,"recruitingSiteCount":12,"countries":["Puerto Rico","United States"]}],"started":"2026-08-03","startedType":"actual","enrolled":600,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/himalayas-1/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"rinzimetostat","kind":"drug","name":"Rinzimetostat","route":"/drugs/rinzimetostat/"}],"company":[{"id":"oric-pharmaceuticals","kind":"company","name":"ORIC Pharmaceuticals","route":"/companies/oric-pharmaceuticals/"}]}}